Differentiated by Innovation & Growth Dr. Gerhard Schmid, President WACKER BIOSOLUTIONS December 3 rd, 2018

Transcription

1 CREATING TOMORROW`S SOLUTIONS Differentiated by Innovation & Growth Dr. Gerhard Schmid, President December 3 rd,

2 Disclaimer The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, other words such as "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. By their nature, forwardlooking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing business or other market conditions and the prospects for growth anticipated by the Company's management. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any statements contained in this presentation, whether as a result of new information, future events or otherwise. In particular, you should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. 1

3 WACKER: Well Positioned for Future Growth OTHERS POLYSILICON No. 1 in merchant market Sales bn SILICONES No. 2 POLYMERS No. 1 BIOSOLUTIONS Leading in niches 2

4 At a Glance Key Figures 206m Sales in Employees Business Units Sales Share Biopharmaceuticals 37m EBITDA in % EBITDA margin in 2017 Food Pharma & Agro BIOSOLUTIONS Sales Growth Innovation 9% CAGR ~50 patents ~30 projects in development 3

5 Focusing on Life Sciences Market Structure by Application Industrials Agro Chemicals 4% 13% Others Sales FY m 52% Food Pharma 29% Our portfolio is built on smart investments and biotechnological expertise 4

6 Biopharmaceuticals An Attractive Market We Are Striving to Become a Leading CMO Recombinant CMO Market ($bn) Our Business Model CAGR +8% CAGR ~9% Drug Development Our Services Drug Substance Manufacturing Outsourcing Formulation Marketing & Sales ~8% Bioprocess Development Cell Banking Production of Biologics, Live Microbials, Vaccines and Polysaccharides Microbial Mammalian Fill & Finish Source: HTBD Bio CM Study

7 Biopharmaceuticals Leveraging Technology with Smart Investments & Innovation Established by R&D and M&A Double Digit Sales Growth ( m) Since 1980s: 2005: : +16% R&D-focus: ESETEC Acquisition of ProThera Extension of production 2014: 2017: 2018: Acquisition of Scil PP with FOLDTEC Installation of new fermenter in Jena Acquisition of SynCo Biopartners 2012* 2013* * Jena only 6

8 Biopharmaceuticals New Technologies and Additional Services after Acquisition Jena/Halle: Cell Line Development Process Development Jena/Halle/Amsterdam: API Manufacturing Amsterdam: Fill & Finish Additional Service ESETEC FOLDTEC Live Microbials Vaccines New Technologies 7

9 Biopharmaceuticals Realizing Synergies with Centers of Excellences at All Sites Jena Halle Amsterdam 350 L: Production of Biologics Process development with focus on late phase / commercial Cell banking 1500 L: Production of Biologics Process development with focus on implementation and early phase development 1500 L/270 L: Production of Biologics / Vaccines / Polysaccharides Single Use Line: Live Microbials Fill & Finish Processes and methods are synchronized across all three sites 8

10 Biopharmaceuticals Core Technologies for Protein Production: ESETEC & FOLDTEC ESETEC secretion technology FOLDTEC refolding technology Inclusion body isolation Protein secretion Inner membrane Periplasmic space Outer cell wall In vitro refolding Active protein 9

11 Biopharmaceuticals Time and Cost-Efficient Manufacturing of Biopharmaceuticals ESETEC (E.coli secretion technology) Fermentation Harvest Example: Medimmune Project Average COGS Savings Homogenization IB preparation Refolding g/l 2.7 up to 5x lower Filtration Chromatography I Chromatography II Chromatography III UF/DF 0.2 Client system (mammalian) ESETEC 2.0 Conventional system ESETEC Bulk Filling ESETEC reduces the number of process steps ESETEC significantly increases yields ESETEC reduces production costs 10

12 Food Cyclodextrins and Cysteine: The Pillars of Our Nutrition Business Cyclodextrin Applications Cysteine Applications Curcumin complex Soluble fiber Dough Softening Vegetarian Savory Flavor Emulsifier Whip-it Vegetarian sausages Taste masking Fat-binding fiber Bakery Probiotics Anti-Fruit Browning 11

13 Food Fermentation Site in León, Spain: Cystine Production and CMO-Business 8x100m 3 capacity Good COGS position Media preparation >15 years experience Scale-up support 12

14 Food Leveraging Our Leading Global Market Position in Gumbase VINNAPAS Resins Innovations S S 13

15 Pharma & Agro Versatile Intermediates for Production of Small Molecule Drugs Chloroacetaldehydedimethylacetal (CADMA) Praziquantel Worm infection Thiamazol Hyperthyroidism Doxofylline Asthma & COPD Midazolam Anesthesia 14

16 Executing Our Growth Strategy Biopharmaceuticals 2014: Acquisition of Scil Proteins Production in Halle 2018: Acquisition of SynCo Biopartners in Amsterdam Biotransformation 2016 onwards: Investments in CDplant Gumbase 2015: Production site in Nanjing Fermentation 2016: Acquisition of assets from ADL 15

17 Strong Growth in Biopharmaceuticals and Pharma & Agro Sales ( m) Highlights 9M +8% Sales growth Higher volumes in Biopharmaceuticals and Pharma & Agro overcompensate lower Cysteine prices EBITDA ( m) 9M M M M 2018 Outlook FY 2018 High-single-digit % sales growth EBITDA impaired by acquisition of SynCo and ramp of León Significant growth expected for Biopharmaceuticals and Pharma & Agro 16

18 Well Positioned for Further Growth Unique Technology Platforms Innovative Solutions Partner Strong Track Record Develop fast growing biotechnology businesses Leveraging our know-how, experience and assets Continuous investments in innovation and growth 17

19 WACKER: Issuer, Contact and Additional Information Issuer and Contact Additional Information INVESTOR RELATIONS CONTACTS Joerg Hoffmann, CFA Tel Monika Stadler Tel ISIN DE000WCH8881 WKN WCH888 Deutsche Börse WCH Scott McCollister Tel Financial Calendar Wacker Chemie AG Hanns-Seidel-Platz 4 D Munich Publications 03/19/19 FY 2018 Results 05/23/19 Annual Shareholders Meeting 04/25/19 Q1 Results /25/19 Q2 Results /30/19 Capital Market Day 10/24/19 Q3 Results 2019 CUSTOMER MAGAZINE FACTBOOK SUSTAINABILITY REPORT 18